Leena Tiainen

Tampere, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Real-world implementation and cost impact analysis of Oncotype DX testing in early-stage breast cancer.

Real-world implementation and cost impact analysis of Oncotype DX testing in early-stage breast cancer.

Journal: PloS one

Published: November 09, 2025

Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study.

Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study.

Journal: Future oncology (London, England)

Published: September 30, 2024

Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.

Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.

Journal: BMC cancer

Published: December 14, 2023

Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy.

Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy.

Journal: Clinical lung cancer

Published: November 10, 2022

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.

Journal: Acta oncologica (Stockholm, Sweden)

Published: October 29, 2022

Breast density and the likelihood of malignant MRI-detected lesions in women diagnosed with breast cancer.

Breast density and the likelihood of malignant MRI-detected lesions in women diagnosed with breast cancer.

Journal: European radiology

Published: October 13, 2022

Radiological and pathological assessment of response to neoadjuvant CDK4/6 inhibitor and endocrine treatments in a real-life setting-initial results.

Radiological and pathological assessment of response to neoadjuvant CDK4/6 inhibitor and endocrine treatments in a real-life setting-initial results.

Journal: Acta radiologica open

Published: May 30, 2021

Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.

Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.

Journal: Acta oncologica (Stockholm, Sweden)

Published: October 01, 2019

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 30, 2019

Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma.

Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma.

Journal: PloS one

Published: February 11, 2019

Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer.

Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer.

Journal: Clinical breast cancer

Published: December 06, 2018

High baseline Tie1 level predicts poor survival in metastatic breast cancer.

High baseline Tie1 level predicts poor survival in metastatic breast cancer.

Journal: BMC cancer

Published: September 20, 2018

Showing 1-12 of 13

Last Updated: 09/26/2026